• 1
    Seror R, Ravaud P, Bowman S, Baron G, Tzioufas A, Theander E, et al.EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index in primary Sjögren's syndrome.Ann Rheum Dis2010;69:11039.
  • 2
    Seror R, Mariette X, Bowman S, Baron G, Gottenberg JE, Boostma H, et al, for the European League Against Rheumatism Sjögren's Task Force.Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index.Arthritis Care Res (Hoboken)2010;62:5518.
  • 3
    Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M, et al.Sjögren's Syndrome disease damage index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients.Arthritis Rheum2007;56:222331.
  • 4
    Bowman SJ, Sutcliffe N, Isenberg DA, Goldblatt F, Adler M, Price E, et al.Sjögren's Systemic Clinical Activity Index (SCAI): a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome.Rheumatology (Oxford)2007;46:184551.
  • 5
    Bowman SJ, Booth DA, Platts RG.Measurement of fatigue and discomfort in primary Sjögren's syndrome using a new questionnaire tool.Rheumatology (Oxford)2004;43:75864.
  • 6
    Bowman SJ, Booth DA, Platts RG, Field A, Rostron J.Validation of the Sicca Symptoms Inventory for clinical studies of Sjögren's syndrome.J Rheumatol2003;30:125966.
  • 7
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al.Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.Ann Rheum Dis2002;61:5548.
  • 8
    Bax HI, Vriesendorp TM, Kallenberg CG, Kalk WW.Fatigue and immune activity in Sjögren's syndrome [abstract].Ann Rheum Dis2002;61:284.
  • 9
    Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al, for the members of the British Isles Lupus Assessment Group (BILAG):development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus.Q J Med1988;69:92737.
  • 10
    Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al.The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.Q J Med1993;86:44758.
  • 11
    Liang MH, Socher SA, Larson MG, Schur PH.Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.Arthritis Rheum1989;32:110718.
  • 12
    Smolen JS, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR, et al.Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis.Ann Rheum Dis2000;59:5045.
  • 13
    Chang E, Abrahamowicz M, Ferland D, Fortin PR.Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians.J Clin Epidemiol2002;55:48897.
  • 14
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, for the Committee on Prognosis Studies in SLE.Derivation of the SLEDAI: a disease activity index for lupus patients.Arthritis Rheum1992;35:63040.
  • 15
    Kwoh CK, O'Connor GT, Regan-Smith MG, Olmstead EM, Brown LA, Burnett JB, et al.Concordance between clinician and patient assessment of physical and mental health status.J Rheumatol1992;19:10317.
  • 16
    Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, et al.A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.Arthritis Rheum2009;61:4827.
  • 17
    Watson RM, Scheel JN, Petri M, Lee LA, Bias WB, McLean RH.Neonatal lupus erythematosus syndrome: analysis of C4 allotypes and C4 genes in 18 families.Medicine (Baltimore)1992;71:8495.
  • 18
    Hay EM, Thomas E, Pal B, Hajeer A, Chambers H, Silman AJ.Weak association between subjective symptoms or and objective testing for dry eyes and dry mouth: results from a population based study.Ann Rheum Dis1998;57:204.
  • 19
    Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL III, Tran-Johnson TK, et al.Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren's syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial.Arch Intern Med1999;159:17481.
  • 20
    Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P.A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.Arthritis Rheum2002;46:74854.
  • 21
    Daniels TE, Cox D, Shiboski CH, Schiodt M, Wu A, Lanfranchi H, et al, for the Sjögren's International Collaborative Clinical Alliance Research Groups.Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren's syndrome among 1,726 registry participants.Arthritis Rheum2011;63:202130.